Positioning no disclosures inside 60 days, left as found
Options put/call open interest 5.00, read 2026-10-25
Ethical does not pass the values gate
Price104.98 USD
Fair value52.49
Ethical score30.0/100
Our investment reviews on this name
2026-10-23Read Markdown103.00+1.9% to today Distribution gives way to Markdown after a 13% slide in 12 days
2026-10-11Read Distribution118.56-11.5% to today ✓Markup gives way to Distribution first Distribution read since July
2026-08-07Read Markup116.91-10.2% to today Distribution gives way to Markup after a 13% rise in 5 weeks
2026-07-02Read Distribution103.41+1.5% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Oppenheimer Holdings Inc. holds its Markdown at $104.98. The statistical read favours the sellers, held for 49 days.
As held on the ledger · 2026-10-27
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 49 days
Price at the screen
$104.98
Valuation
11.42 trailing · 41.01 forward price to earnings
Values screen
FAIL· score 30.0
Beta
1.10
The Workings
Five Screens, Shown in Full
Does not pass. Prohibited keyword in sector/industry: financial services
Test
Figure
Limit
What it means
Status
Business activity
Excluded
Core business clean
Prohibited keyword in sector/industry: financial services
Fail
Debt load
Excluded
Below 33%
Interest-bearing debt is of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
Excluded
Below 33%
Interest-bearing cash and securities are of assets, above the one-third limit.
Fail
Receivables
Excluded
Below 49%
Money owed to the company is of assets, above the 49% limit.
Fail
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Oppenheimer does not clear the screen at the business-activity stage. It operates in conventional financial services, which the screen treats as interest-based, so the financial ratios are not the deciding factor here.
Read as at 2026-10-27. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when OPY's ethical verdict changes
Today OPY does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-27 screen. The gold marker is the market price at the same screen. The price runs 50.0% above the base estimate.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-27 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Broker dealers rarely earn their premium price tags
Picture a middle market broker helping clients move bonds and equities every day. The business still fails our ethical screen outright because it sits inside financial services. That single red flag ends the conversation before any numbers get considered.
Revenue is growing at 23 percent yet the shares trade at 42.6 times forward earnings with only a 6 percent profit margin and 11 percent return on equity. Our fair value sits at half the current price, leaving a 50 percent negative margin of safety and an opportunity rating of none.
Currency moves and deal flow swings add normal cyclical risk but the ethical screen remains the decisive barrier. We pass without hesitation. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
OPY trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-28Markdown$104.98+1.9%Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 6% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 62%. Our forward projection puts the odds of a 10% gain over the next month near 32%. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Markdown$103.00+0.0%Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 6% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 62%. Our forward projection puts the odds of a 10% gain over the next month near 32%. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Markdown$103.00+0.0%Entry 12
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 6% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 62%. Our forward projection puts the odds of a 10% gain over the next month near 32%. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markdown$103.00+0.0%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 62%. Our forward projection puts the odds of a 10% gain over the next month near 32%. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Markdown$103.00+0.0%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 62%. Our forward projection puts the odds of a 10% gain over the next month near 32%. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Markdown · changed$103.00+0.0%Entry 9
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 62%. Our forward projection puts the odds of a 10% gain over the next month near 32%. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Distribution$103.00-13.1%Entry 8
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 13.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 62%. Our forward projection puts the odds of a 10% gain over the next month near 32%.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 62%. Our forward projection puts the odds of a 10% gain over the next month near 32%.
2026-10-02Markup$118.56-3.5%Entry 6
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 3.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 62%. Our forward projection puts the odds of a 10% gain over the next month near 32%.
2026-09-08Markup$122.89+5.1%Entry 5
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 62%. Our forward projection puts the odds of a 10% gain over the next month near 32%.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
